Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970787 | 0.74 | SLC6A3 (0.56) | ACHESIGMAR1SLC6A3OPRM1HTR1A | |
| SCHEMBL8970769 | 0.74 | SLC6A3 (0.56) | ACHESIGMAR1SLC6A3OPRM1HTR1A | |
| SCHEMBL21726765 | 0.73 | SLC6A3 (0.59) | ACHESIGMAR1SLC6A3HTR1ADRD2 | |
| SCHEMBL6056974 | 0.73 | SLC6A3 (0.83) | ACHESIGMAR1SLC6A3HTR1ADRD2 | |
| SCHEMBL7264546 | 0.73 | SLC6A3 (0.83) | ACHESIGMAR1SLC6A3HTR1ADRD2 | |
| SCHEMBL14407778 | 0.73 | SLC6A3 (0.83) | ACHESIGMAR1SLC6A3HTR1ADRD2 | |
| SCHEMBL13150782 | 0.73 | SLC6A3 (0.83) | ACHESIGMAR1SLC6A3HTR1ADRD2 | |
| SCHEMBL3566447 | 0.73 | SLC6A3 (0.54) | ACHESIGMAR1SLC6A3OPRM1 | |
| SCHEMBL8970828 | 0.73 | SIGMAR1 (0.56) | ACHESIGMAR1SLC6A3OPRM1 | |
| SCHEMBL27638865 | 0.73 | SLC6A3 (0.63) | ACHESIGMAR1SLC6A3HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221314-B1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-07-03 | — | — | EP | disclosed |